I. COMMENCED TRADING IN JULY | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
| ||||||||
INITIAL OFFERINGS | ||||||||
| ||||||||
There were no initial public offerings that commenced in July. | ||||||||
| ||||||||
Total: $0M | ||||||||
| ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (US$M) |
Post-Offering Market Cap (M)% |
| ||||||||
FOLLOW-ON OFFERINGS | ||||||||
| ||||||||
BioMimetic Therapeutics Inc. (BMTI)1 |
7/14 |
7/15 |
5.64S |
$8.50 |
27.74 |
J.P. Morgan Securities |
$47.94 |
$235.79 |
| ||||||||
Total: $47.94M | ||||||||
| ||||||||
Notes: | ||||||||
|
II. FILED AND PENDING | ||||||||
| ||||||||
Company (Symbol)# |
Date Filed |
Shares/Units (M) |
Price |
Shares Out |
Lead, Other Underwriters (M)@ |
Gross (US$M) |
||
| ||||||||
INITIAL OFFERINGS | ||||||||
| ||||||||
Aldagen Inc. (ALDH) |
10/29/09 |
Units |
N/A |
N/A |
Boenning & Scattergood |
$46 |
||
| ||||||||
BG Medicine Inc. (BGMD) |
1/29/10 |
N/A |
N/A |
N/A |
Jefferies & Co. |
$86.25 |
||
| ||||||||
Human Stem Cell Institute (Russia)1 |
10/7/09 |
15S |
RUB 9-11 |
N/A |
N/A |
$5.025 |
||
| ||||||||
Ikaria Inc. (IKAR) |
5/13/10 |
N/A |
N/A |
N/A |
Goldman Sachs |
$200 |
||
| ||||||||
Med BioGene Inc. (Canada; CDNX:MBI)2 |
12/28/09 |
N/A |
N/A |
N/A |
Rodman & Renshaw LLC |
$24 |
||
| ||||||||
NuPathe Inc. (PATH)3 |
5/14/10 |
5S |
$14-$16 |
14. 1 |
Leerink Swann |
$75 |
||
| ||||||||
Prometheus Laboratories Inc. (RXDX) |
12/19/07 |
N/A |
N/A |
N/A |
Goldman Sachs & Co. |
$151.3 |
||
| ||||||||
Trius Therapeutics Inc. (TSRX)4 |
11/6/09 |
10S |
$5 |
23.6 |
Citibank |
$50 |
||
| ||||||||
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; CDNX = Canadian Venture Exchange; General shelf registration statements are not included until action is taken on the filing; * Stock symbols for companies seeking to complete IPOs are proposed; @ This column reflects the shares outstanding following the offering, when disclosed; N/A = Not available, applicable or reported; The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing; 1 Human Stem Cell's IPO is filed for the Moscow Interbank Currency Exchange. 2 Med BioGene secured Rodman & Renshaw for an IPO in the U.S. 3 NuPathe's overallotment option: 750,000 shares. 4 Trius' overallotment option: 750,000 shares. |